39177111|t|Contribution of alpha-synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI.
39177111|a|INTRODUCTION: The in vivo detection of mixed Alzheimer's disease (AD) and alpha-synuclein (alphaSyn) pathology is important for clinical management and prognostic stratification. We investigated the contribution of alphaSyn pathology, detected by cerebrospinal fluid (CSF) seed amplification assay (alphaSyn SAA), on [18F]-fluorodeoxyglucose positron emission tomography (FDG PET) pattern in subjects with amnestic mild cognitive impairment (aMCI). METHODS: We included 562 aMCI participants and 204 cognitively normal controls (CN) with available alphaSyn SAA and cerebral metabolic rate for glucose utilization (rCMRgl) data. RESULTS: 24% of aMCI cases were positive (+) for CSF alphaSyn SAA. Compared to CN, both alphaSyn+ and negative (-) aMCI participants showed reductions in rCMRgl within AD typical regions. alphaSyn+ aMCI had lower rCMRgl within AD and dementia with Lewy bodies (DLB) typical regions compared to alphaSyn- aMCI, even after stratification according to the CSF AT(N) system. DISCUSSION: alphaSyn pathology contributes to a distinct FDG PET pattern in aMCI. HIGHLIGHTS: alphaSyn pathology can be detected in vivo by CSF alphaSyn SAA. We investigated the FDG PET pattern in aMCI patients with CSF alphaSyn SAA positivity. alphaSyn+ aMCI showed a marked brain hypometabolism in AD and DLB typical regions.
39177111	16	31	alpha-synuclein	Gene	6622
39177111	54	61	glucose	Chemical	MESH:D005947
39177111	76	84	patients	Species	9606
39177111	90	102	amnestic MCI	Disease	MESH:D000425
39177111	149	168	Alzheimer's disease	Disease	MESH:D000544
39177111	170	172	AD	Disease	MESH:D000544
39177111	178	193	alpha-synuclein	Gene	6622
39177111	195	203	alphaSyn	Gene	6622
39177111	319	327	alphaSyn	Gene	6622
39177111	403	411	alphaSyn	Gene	6622
39177111	412	415	SAA	Gene	6287
39177111	421	445	[18F]-fluorodeoxyglucose	Chemical	MESH:D019788
39177111	476	479	FDG	Chemical	MESH:D019788
39177111	510	544	amnestic mild cognitive impairment	Disease	MESH:D060825
39177111	546	550	aMCI	Disease	MESH:D060825
39177111	578	582	aMCI	Disease	MESH:D060825
39177111	652	660	alphaSyn	Gene	6622
39177111	661	664	SAA	Gene	6287
39177111	697	704	glucose	Chemical	MESH:D005947
39177111	748	752	aMCI	Disease	MESH:D060825
39177111	785	793	alphaSyn	Gene	6622
39177111	794	797	SAA	Gene	6287
39177111	820	828	alphaSyn	Gene	6622
39177111	847	851	aMCI	Disease	MESH:D060825
39177111	900	902	AD	Disease	MESH:D000544
39177111	920	928	alphaSyn	Gene	6622
39177111	930	934	aMCI	Disease	MESH:D060825
39177111	959	961	AD	Disease	MESH:D000544
39177111	966	991	dementia with Lewy bodies	Disease	MESH:D020961
39177111	993	996	DLB	Disease	MESH:D020961
39177111	1026	1034	alphaSyn	Gene	6622
39177111	1036	1040	aMCI	Disease	MESH:D060825
39177111	1115	1123	alphaSyn	Gene	6622
39177111	1160	1163	FDG	Chemical	MESH:D019788
39177111	1179	1183	aMCI	Disease	MESH:D060825
39177111	1197	1205	alphaSyn	Gene	6622
39177111	1247	1255	alphaSyn	Gene	6622
39177111	1256	1259	SAA	Gene	6287
39177111	1281	1284	FDG	Chemical	MESH:D019788
39177111	1300	1304	aMCI	Disease	MESH:D060825
39177111	1305	1313	patients	Species	9606
39177111	1323	1331	alphaSyn	Gene	6622
39177111	1332	1335	SAA	Gene	6287
39177111	1348	1356	alphaSyn	Gene	6622
39177111	1358	1362	aMCI	Disease	MESH:D060825
39177111	1385	1399	hypometabolism	Disease	
39177111	1403	1405	AD	Disease	MESH:D000544
39177111	1410	1413	DLB	Disease	MESH:D020961
39177111	Association	MESH:D020961	6622
39177111	Association	MESH:D000425	6622
39177111	Association	MESH:D005947	MESH:D000425
39177111	Association	MESH:D060825	6287
39177111	Association	MESH:D019788	6622
39177111	Association	MESH:D000544	6622
39177111	Association	MESH:D060825	6622
39177111	Association	MESH:D005947	6622
39177111	Association	MESH:D019788	MESH:D060825

